Mitchell C.C. Liu, MDCM, FRCPC is a Clinical Associate Professor of Radiation Oncology at, BC Cancer Vancouver Center. Dr. Liu completed his radiation oncology residency at McGill University and a radiation oncology fellowship at Massachusetts General Hospital in Boston. He is currently in the Lung and GI team and has been involved in SABR treatments of lung, liver, spine and oligometastases. He has been involved in SABR clinical trials including: SABR-COMET, COMET-3, CCTG SC.24, etc
Oligometastatic diseases are essentially early metastases which are limited in number and location. The hypothesis is that in carefully selected patients, aggressive local treatment (such as surgery, RFA or Stereotactic ablative radiotherapy (SBRT/SABR)) could improve their clinical outcome. The identified prognostic factors tend to be related to: young age, patient fitness, slow-growing disease (i.e., metachronous metastases or a long disease free interval between the original cancer and the metastatic recurrence), low disease burden (i.e., a smaller number of metastases) and effective use of systemic therapies. SABR-COMET which randomized patients to have SABR vs Standard of Care showed that the SABR arm has better local control and PFS , as well there is a trend of improvement in OS. Updates on this study and other SABR trials will be presented.